JP2019535754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535754A5 JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- compound
- pharmaceutically acceptable
- equation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O Chemical compound CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425810P | 2016-11-23 | 2016-11-23 | |
| US62/425,810 | 2016-11-23 | ||
| PCT/US2017/063182 WO2018098390A1 (en) | 2016-11-23 | 2017-11-24 | Albumin-binding psma inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535754A JP2019535754A (ja) | 2019-12-12 |
| JP2019535754A5 true JP2019535754A5 (enExample) | 2021-01-07 |
| JP7167021B2 JP7167021B2 (ja) | 2022-11-08 |
Family
ID=60812130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527426A Active JP7167021B2 (ja) | 2016-11-23 | 2017-11-24 | アルブミン結合ｐｓｍａ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11147889B2 (enExample) |
| EP (1) | EP3544960A1 (enExample) |
| JP (1) | JP7167021B2 (enExample) |
| CN (1) | CN109982998A (enExample) |
| BR (1) | BR112019010206A2 (enExample) |
| CA (1) | CA3043619A1 (enExample) |
| MX (1) | MX2019005742A (enExample) |
| WO (1) | WO2018098390A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102884167B1 (ko) * | 2017-10-22 | 2025-11-12 | 프로빈셜 헬스 서비시즈 오쏘리티 | 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물 |
| WO2019246445A1 (en) * | 2018-06-20 | 2019-12-26 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| US20220009883A1 (en) * | 2018-11-14 | 2022-01-13 | Noria Therapeutics, Inc. | Thioamide-containing compositions and methods of use thereof |
| WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| US12472272B2 (en) | 2019-04-17 | 2025-11-18 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer |
| KR20220024595A (ko) | 2019-06-21 | 2022-03-03 | 프로빈셜 헬스 서비시즈 오쏘리티 | 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물 |
| WO2021177390A1 (ja) | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
| MX2022013783A (es) * | 2020-05-06 | 2023-04-19 | Univ Cornell | Compuestos tratanosticos que contienen cobre y metodos de uso. |
| CA3203175A1 (en) * | 2020-12-04 | 2022-06-09 | The Regents Of The University Of California | Peptide receptor radionuclide therapy |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| AU2022228911A1 (en) * | 2021-03-04 | 2023-09-21 | Kyoto University | Compound and radioactive labeling compound |
| JP2025507971A (ja) * | 2022-03-04 | 2025-03-21 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | 前立腺特異的膜抗原を標的とする放射性標識化合物 |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| CN118496305A (zh) * | 2023-02-16 | 2024-08-16 | 无锡诺宇医药科技有限公司 | Psma靶向放射性药物及其合成和应用 |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| LT3964502T (lt) | 2009-03-19 | 2024-08-26 | The Johns Hopkins University | Junginiai nukreipti į psma ir jų panaudojimas |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| WO2013028664A1 (en) | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
| US20160257961A1 (en) | 2013-11-06 | 2016-09-08 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| ES2912753T3 (es) | 2014-08-24 | 2022-05-27 | Max Planck Gesellschaft Zur Foerderung Der Wss | Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA |
| HRP20210183T1 (hr) * | 2015-09-30 | 2021-04-30 | Deutsches Krebsforschungszentrum | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate |
| PL3433238T3 (pl) * | 2016-03-22 | 2021-12-13 | The Johns Hopkins University | Środki o wysokim powinowactwie ukierunkowane na antygen błonowy specyficzny dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego |
| SG11201811482YA (en) * | 2016-06-23 | 2019-01-30 | Univ Cornell | Double targeted constructs to affect tumor kill |
| DE102016122273B4 (de) | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
-
2017
- 2017-11-24 MX MX2019005742A patent/MX2019005742A/es unknown
- 2017-11-24 BR BR112019010206A patent/BR112019010206A2/pt not_active Application Discontinuation
- 2017-11-24 WO PCT/US2017/063182 patent/WO2018098390A1/en not_active Ceased
- 2017-11-24 US US16/349,756 patent/US11147889B2/en active Active
- 2017-11-24 CN CN201780071927.6A patent/CN109982998A/zh active Pending
- 2017-11-24 JP JP2019527426A patent/JP7167021B2/ja active Active
- 2017-11-24 EP EP17821755.0A patent/EP3544960A1/en not_active Withdrawn
- 2017-11-24 CA CA3043619A patent/CA3043619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535754A5 (enExample) | ||
| CN101668547B (zh) | 选择缺氧组织的弱碱性2-硝基咪唑递送剂及其应用方法 | |
| US8435489B2 (en) | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | |
| US11147889B2 (en) | Albumin-binding PSMA inhibitors | |
| JP2018058847A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| JP2018199694A5 (enExample) | ||
| RU2011146362A (ru) | Набор для предварительного таргетинга, способ и средства, используемые в нем | |
| JP2010523599A5 (enExample) | ||
| WO2008124651A3 (en) | Nitro-imidazole hypoxia imaging agents | |
| JP2013521287A5 (enExample) | ||
| JP2010511704A5 (enExample) | ||
| CA3030907A1 (en) | Chelated psma inhibitors | |
| JP2015528814A5 (enExample) | ||
| JP2012504131A5 (enExample) | ||
| CA2722858C (en) | Substrate based pet imaging agents | |
| JP2009538894A5 (enExample) | ||
| Das et al. | 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis | |
| Subbarayan et al. | Evaluation studies of technetium-99m-porphyrin (T3, 4BCPP) for tumor imaging | |
| Welch et al. | Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides | |
| JP2024542261A (ja) | 診療に寄与する新規ホウ素リポソーム | |
| JP2018511648A5 (enExample) | ||
| US20090028791A1 (en) | Dichloroacetate Analogs as Imaging Agents | |
| Sartor et al. | Stromal targeted therapy in bone metastatic prostate cancer: promise delivered | |
| JPWO2023059695A5 (enExample) |